BusinessAchieve Life Sciences Reports Q1 2026 Financial Results and Business Updates
Achieve Life Sciences announced its Q1 2026 financial results, including a private placement raising up to $354 million to fund cytisinicline development for nicotine dependence. The company appointed Andrew D. Goldberg as CEO, expanded its board, and partnered with Adare Pharma for U.S. manufacturing. FDA review is ongoing with a PDUFA date of June 20, 2026, targeting a commercial launch in H1 2027.
The Manila Times··Seattle




